Although MTAP deletion sensitizes cancer cells to PRMT5 depletion, pharmacologic inhibition of PRMT5 by a specific small‐molecule inhibitor shows only modest selective tumor cytotoxicity (Kryukov et al, 2016; Marjon et al, 2016; Mavrakis et al, 2016). The gene discussed is PRMT5; the disease is cancer.